Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 852-873

  Ghiringhelli, François ^a,b,c   Rébé, Cédric ^b,c   Hichami, Aziz ^a,b   Delmas, Dominique ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b INSERM   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Cancer; Cytokines; Dendritic cells; Immune system; Inflammation; Interleukins; Lipid mediators; Macrophages; NK cells; NO; Polyphenols; ROS; T cells; TNF; Transcription factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CAFFEIC ACID; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 9; PROSTAGLANDIN SYNTHASE; QUERCETIN; RESVERATROL; SCAVENGER RECEPTOR A; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; B LYMPHOCYTE; BLADDER CANCER; BREAST CANCER; BURKITT LYMPHOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER THERAPY; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TARGETING; EFFECTOR CELL; GLIOBLASTOMA; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MACROPHAGE; MELANOMA; MEMORY CELL; MESOTHELIOMA; METASTATIC MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHAGOCYTOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMACH CANCER; STOMACH CARCINOMA; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; HUMANS; IMMUNOMODULATION; NEOPLASMS; POLYPHENOLS;

EID: 84866364643     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650048     Document Type: Review

References (308)

1. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J. and Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410, 1107-1111.
2. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; Rubin, S.C. and Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 2003, 348, 203-213.
3. Pages, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; Meatchi, T.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H. and Galon, J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med., 2005, 353, 2654-2666.
4. Woo, E.Y.; Chu, C.S.; Goletz, T.J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S.C.; Kaiser, L.R. and June, C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res., 2001, 61, 4766-4772.
5. Ghiringhelli, F.; Larmonier, N.; Schmitt, E.; Parcellier, A.; Cathelin, D.; Garrido, C.; Chauffert, B.; Solary, E.; Bonnotte, B. and Martin, F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol., 2004, 34, 336-344.
6. Ghiringhelli, F.; Menard, C.; Puig, P.E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L. and Chauffert, B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother., 2007, 56, 641-648.
7. Roux, S.; Apetoh, L.; Chalmin, F.; Ladoire, S.; Mignot, G.; Puig, P.E.; Lauvau, G.; Zitvogel, L.; Martin, F.; Chauffert, B.; Yagita, H.; Solary, E. and Ghiringhelli, F. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J. Clin. Invest., 2008, 118, 3751-3761.
8. Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A.A.; Frosina, D.; Gnjatic, S.; Ambrosone, C.; Kepner, J.; Odunsi, T.; Ritter, G.; Lele, S.; Chen, Y.T.; Ohtani, H.; Old, L.J. and Odunsi, K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA, 2005, 102, 18538-18543.
9. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol., 2004, 4, 941-952.
10. Anaissie, E.J.; Kontoyiannis, D.P.; O'Brien, S.; Kantarjian, H.; Robertson, L.; Lerner, S. and Keating, M.J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med., 1998, 129, 559-566.
11. Su, Y.B.; Sohn, S.; Krown, S.E.; Livingston, P.O.; Wolchok, J.D.; Quinn, C.; Williams, L.; Foster, T.; Sepkowitz, K.A. and Chapman, P.B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol., 2004, 22, 610-616.
12. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F.J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J.P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G. and Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 2007, 13, 1050-1059.
13. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; Perfettini, J.L.; Schlemmer, F.; Tasdemir, E.; Uhl, M.; Genin, P.; Civas, A.; Ryffel, B.; Kanellopoulos, J.; Tschopp, J.; Andre, F.; Lidereau, R.; McLaughlin, N.M.; Haynes, N.M.; Smyth, M.J.; Kroemer, G. and Zitvogel, L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med., 2009, 15, 1170-1178.
14. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rebe, C. and Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res., 2010, 70, 3052-3061.
15. Renaud, S.C.; Gueguen, R.; Schenker, J. and d'Houtaud, A. Alcohol and mortality in middle-aged men from eastern France. Epidemiology, 1998, 9, 184-188.
16. Levi, F.; Pasche, C.; Lucchini, F.; Ghidoni, R.; Ferraroni, M. and La Vecchia, C. Resveratrol and breast cancer risk. Eur. J. Cancer Prev., 2005, 14, 139-142.
17. Knekt, P.; Jarvinen, R.; Seppanen, R.; Hellovaara, M.; Teppo, L.; Pukkala, E. and Aromaa, A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am. J. Epidemiol., 1997, 146, 223-230.
18. Heijnen, C.G.; Haenen, G.R.; Vekemans, J.A. and Bast, A. Peroxynitrite scavenging of flavonoids: structure activity relationship. Environ. Toxicol. Pharmacol., 2001, 10, 199-206.
19. Cao, G.; Sofic, E. and Prior, R.L. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic. Biol. Med., 1997, 22, 749-760.
20. Boots, A.W.; Kubben, N.; Haenen, G.R. and Bast, A. Oxidized quercetin reacts with thiols rather than with ascorbate: implication for quercetin supplementation. Biochem. Biophys. Res. Commun., 2003, 308, 560-565.
21. Loa, J.; Chow, P. and Zhang, K. Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells. Cancer Chemother. Pharmacol., 2009, 63, 1007-1016.
22. Yang, F.; Oz, H.S.; Barve, S.; de Villiers, W.J.; McClain, C.J. and Varilek, G.W. The green tea polyphenol (-)-epigallocatechin-3gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol., 2001, 60, 528-533.
23. Chung, J.Y.; Huang, C.; Meng, X.; Dong, Z. and Yang, C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res., 1999, 59, 4610-4617.
24. Nam, S.; Smith, D.M. and Dou, Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem., 2001, 276, 13322-13330.
25. Saeki, K.; Hayakawa, S.; Isemura, M. and Miyase, T. Importance of a pyrogallol-type structure in catechin compounds for apoptosis-inducing activity. Phytochemistry, 2000, 53, 391-394.
26. Murias, M.; Jager, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H. and Gille, L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol., 2005, 69, 903-912.
27. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66, 663-673.
28. Yang, C.S.; Kim, S.; Yang, G.Y.; Lee, M.J.; Liao, J.; Chung, J.Y. and Ho, C.T. Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Proc. Soc. Exp. Biol. Med., 1999, 220, 213-217.
29. Zaveri, N.T. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci., 2006, 78, 2073-2080.
30. Link, A.; Balaguer, F. and Goel, A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol., 2010, 80, 1771-1792.
31. Swann, J.B. and Smyth, M.J. Immune surveillance of tumors. J. Clin. Invest., 2007, 117, 1137-1146.
32. Shiku, H. Importance of CD4+ helper T-cells in antitumor immunity. Int. J. Hematol., 2003, 77, 435-438.
33. Tuting, T.; Storkus, W.J. and Lotze, M.T. Gene-based strategies for the immunotherapy of cancer. J. Mol.Med.(Berl), 1997, 75, 478-491.
34. Hadden, J.W. Immunodeficiency and cancer: prospects for correction. Int. Immunopharmacol., 2003, 3, 1061-1071.
35. Wan, Y.Y. and Flavell, R.A. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol. Rev., 2007, 220, 199-213.
36. Ohkura, N.; Hamaguchi, M. and Sakaguchi, S. FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol. Sci., 2011, 32, 158-166.
37. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; McGrady, G. and Wahl, S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med., 2003, 198, 1875-1886.
38. Yang, Y.; Paik, J.H.; Cho, D.; Cho, J.A. and Kim, C.W. Resveratrol induces the suppression of tumor-derived CD4(+)CD25(+) regulatory T cells. Int. Immunopharmacol., 2008, 8, 542-547.
39. Bhattacharyya, S.; Md Sakib Hossain, D.; Mohanty, S.; Sankar Sen, G.; Chattopadhyay, S.; Banerjee, S.; Chakraborty, J.; Das, K.; Sarkar, D.; Das, T. and Sa, G. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol. Immunol., 2010, 7, 306-315.
40. Guo, T.L.; Chi, R.P.; Hernandez, D.M.; Auttachoat, W. and Zheng, J.F. Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein. Carcinogenesis, 2007, 28, 2560-2566.
41. Forward, N.A.; Conrad, D.M.; Power Coombs, M.R.; Doucette, C.D.; Furlong, S.J.; Lin, T.J. and Hoskin, D.W. Curcumin blocks interleukin (IL)-2 signaling in T-lymphocytes by inhibiting IL-2 synthesis, CD25 expression, and IL-2 receptor signaling. Biochem. Biophys. Res. Commun., 2011, 407, 801-806.
42. Cong, Y.; Wang, L.; Konrad, A.; Schoeb, T. and Elson, C.O. Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur. J. Immunol., 2009, 39, 3134-3146.
43. Groux, H.; O'Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E. and Roncarolo, M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389, 737-742.
44. Wong, C.P.; Nguyen, L.P.; Noh, S.K.; Bray, T.M.; Bruno, R.S. and Ho, E. Induction of regulatory T cells by green tea polyphenol EGCG. Immunol. Lett., 2011, 139, 7-13.
45. Ghiringhelli, F.; Menard, C.; Terme, M.; Flament, C.; Taieb, J.; Chaput, N.; Puig, P.E.; Novault, S.; Escudier, B.; Vivier, E.; Lecesne, A.; Robert, C.; Blay, J.Y.; Bernard, J.; Caillat-Zucman, S.; Freitas, A.; Tursz, T.; Wagner-Ballon, O.; Capron, C.; Vainchencker, W.; Martin, F. and Zitvogel, L. CD4+CD25+regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med., 2005, 202, 1075-1085.
46. Ghiringhelli, F.; Puig, P.E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B. and Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGFbeta- secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med., 2005, 202, 919-929.
47. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature, 2001, 411, 380-384.
48. Mantena, S.K.; Roy, A.M. and Katiyar, S.K. Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem. Photobiol., 2005, 81, 1174-1179.
49. Song, C.K.; Han, H.D.; Noh, K.H.; Kang, T.H.; Park, Y.S.; Kim, J.H.; Park, E.S.; Shin, B.C. and Kim, T.W. Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol. Ther., 2007, 15, 1558-1563.
50. Kang, T.H.; Lee, J.H.; Song, C.K.; Han, H.D.; Shin, B.C.; Pai, S.I.; Hung, C.F.; Trimble, C.; Lim, J.S.; Kim, T.W. and Wu, T.C. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res., 2007, 67, 802-811.
51. Churchill, M.; Chadburn, A.; Bilinski, R.T. and Bertagnolli, M.M. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J. Surg. Res., 2000, 89, 169-175.
52. Sharma, S.; Chopra, K.; Kulkarni, S.K. and Agrewala, J.N. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol, 2007, 147, 155-163.
53. Ansari, M.J. and Sayegh, M.H. Costimulation couture: a designer approach to regulating autoimmunity. J. Clin. Invest., 2006, 116, 2080-2083.
54. Thomson, A.W. and Forrester, J.V. Therapeutic advances in immunosuppression. Clin. Exp. Immunol., 1994, 98, 351-357.
55. Akdis, C.A. and Blaser, K. Mechanisms of interleukin-10-mediated immune suppression. Immunology, 2001, 103, 131-136.
56. Kim, W.; Fan, Y.Y.; Smith, R.; Patil, B.; Jayaprakasha, G.K.; McMurray, D.N. and Chapkin, R.S. Dietary curcumin and limonin suppress CD4+ T-cell proliferation and interleukin-2 production in mice. J. Nutr., 2009, 139, 1042-1048.
57. Fahey, A.J.; Adrian Robins, R. and Constantinescu, C.S. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J. Cell Mol. Med., 2007, 11, 1129-1137.
58. Skyberg, J.A.; Robison, A.; Golden, S.; Rollins, M.F.; Callis, G.; Huarte, E.; Kochetkova, I.; Jutila, M.A. and Pascual, D.W. Apple polyphenols require T cells to ameliorate dextran sulfate sodiuminduced colitis and dampen proinflammatory cytokine expression. J. Leukoc. Biol., 2011.
59. Imler, T.J., Jr. and Petro, T.M. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFNgamma+cells, and decreased macrophage IL-6 expression. Int. Immunopharmacol., 2009, 9, 134-143.
60. Radwan, F.F.; Zhang, L.; Hossain, A.; Doonan, B.P.; God, J. and Haque, A. Mechanisms regulating enhanced HLA class II-mediated CD4+ T cell recognition of human B-cell lymphoma by resveratrol. Leuk. Lymphoma, 2011.
61. Ranjan, D.; Siquijor, A.; Johnston, T.D.; Wu, G. and Nagabhuskahn, M. The effect of curcumin on human B-cell immortalization by Epstein-Barr virus. Am. Surg., 1998, 64, 47-51; discussion 51-42.
62. Billard, C.; Izard, J.C.; Roman, V.; Kern, C.; Mathiot, C.; Mentz, F. and Kolb, J.P. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma, 2002, 43, 1991-2002.
63. Sica, A.; Allavena, P. and Mantovani, A. Cancer related inflammation: the macrophage connection. Cancer Lett., 2008, 267, 204-215.
64. Murphy, E.A.; Davis, J.M.; McClellan, J.L. and Carmichael, M.D. Quercetin's effects on intestinal polyp multiplicity and macrophage number in the Apc(Min/+) mouse. Nutr Cancer 63, 421-426.
65. Orsolic, N. and Basic, I. Water-soluble derivative of propolis and its polyphenolic compounds enhance tumoricidal activity of macrophages. J. Ethnopharmacol., 2005, 102, 37-45.
66. Houde, V.; Grenier, D. and Chandad, F. Protective effects of grape seed proanthocyanidins against oxidative stress induced by lipopolysaccharides of periodontopathogens. J. Periodontol., 2006, 77, 1371-1379.
67. Alvarez, E.; Leiro, J. and Orallo, F. Effect of (-)-epigallocatechin-3-gallate on respiratory burst of rat macrophages. Int. Immunopharmacol., 2002, 2, 849-855.
68. Joe, B. and Lokesh, B.R. Dietary n-3 fatty acids, curcumin and capsaicin lower the release of lysosomal enzymes and eicosanoids in rat peritoneal macrophages. Mol. Cell Biochem., 2000, 203, 153-161.
69. Brouet, I. and Ohshima, H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophys. Res. Commun., 1995, 206, 533-540.
70. Varalakshmi, C.; Ali, A.M.; Pardhasaradhi, B.V.; Srivastava, R.M.; Singh, S. and Khar, A. Immunomodulatory effects of curcumin: invivo. Int. Immunopharmacol., 2008, 8, 688-700.
71. Guo, L.Y.; Cai, X.F.; Lee, J.J.; Kang, S.S.; Shin, E.M.; Zhou, H.Y.; Jung, J.W. and Kim, Y.S. Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. Arch. Pharm. Res., 2008, 31, 490-496.
72. Tsai, S.H.; Lin-Shiau, S.Y. and Lin, J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol., 1999, 126, 673-680.
73. Matsuda, H.; Kageura, T.; Morikawa, T.; Toguchida, I.; Harima, S. and Yoshikawa, M. Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages. Bioorg. Med. Chem. Lett., 2000, 10, 323-327.
74. Chan, M.M.; Mattiacci, J.A.; Hwang, H.S.; Shah, A. and Fong, D. Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. Biochem. Pharmacol., 2000, 60, 1539-1548.
75. Lin, Y.L. and Lin, J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol., 1997, 52, 465-472.
76. Lee, S.J.; Lee, I.S. and Mar, W. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose in murine macrophage cells. Arch. Pharm. Res., 2003, 26, 832-839.
77. Marczin, N.; Papapetropoulos, A. and Catravas, J.D. Tyrosine kinase inhibitors suppress endotoxin-and IL-1 beta-induced NO synthesis in aortic smooth muscle cells. Am. J. Physiol., 1993, 265, H1014-1018.
78. Chan, M.M.; Huang, H.I.; Fenton, M.R. and Fong, D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem. Pharmacol., 1998, 55, 1955-1962.
79. Gafner, S.; Lee, S.K.; Cuendet, M.; Barthelemy, S.; Vergnes, L.; Labidalle, S.; Mehta, R.G.; Boone, C.W. and Pezzuto, J.M. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry, 2004, 65, 2849-2859.
80. Bhaumik, S.; Jyothi, M.D. and Khar, A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett., 2000, 483, 78-82.
81. Sreejayan and Rao, M.N. Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol., 1997, 49, 105-107.
82. Antony, S.; Kuttan, R. and Kuttan, G. Immunomodulatory activity of curcumin. Immunol. Invest., 1999, 28, 291-303.
83. Bisht, K.; Choi, W.H.; Park, S.Y.; Chung, M.K. and Koh, W.S. Curcumin enhances non-inflammatory phagocytic activity of RAW264.7 cells. Biochem. Biophys. Res. Commun., 2009, 379, 632-636.
84. Li, X. and Liu, X. Effect of curcumin on immune function of mice. J Huazhong Univ Sci Technolog Med Sci, 2005, 25, 137-140.
85. Monobe, M.; Ema, K.; Tokuda, Y. and Maeda-Yamamoto, M. Enhancement of phagocytic activity of macrophage-like cells by pyrogallol-type green tea polyphenols through caspase signaling pathways. Cytotechnology, 62, 201-203.
86. Yu, C.S.; Lai, K.C.; Yang, J.S.; Chiang, J.H.; Lu, C.C.; Wu, C.L.; Lin, J.P.; Liao, C.L.; Tang, N.Y.; Wood, W.G. and Chung, J.G. Quercetin inhibited murine leukemia WEHI-3 cells in vivo and promoted immune response. Phytother Res., 24, 163-168.
87. Bertelli, A.A.; Ferrara, F.; Diana, G.; Fulgenzi, A.; Corsi, M.; Ponti, W.; Ferrero, M.E. and Bertelli, A. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int. J. Tissue React., 1999, 21, 93-104.
88. Leiro, J.; Alvarez, E.; Garcia, D. and Orallo, F. Resveratrol modulates rat macrophage functions. Int Immunopharmacol, 2002, 2, 767-774.
89. Kowalski, J.; Samojedny, A.; Paul, M.; Pietsz, G. and Wilczok, T. Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor-alpha genes in J774.2 macrophages. Pharmacol. Rep., 2005, 57, 390-394.
90. Yang, F.; de Villiers, W.J.; McClain, C.J. and Varilek, G.W. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J. Nutr., 1998, 128, 2334-2340.
91. Murakami, A.; Takahashi, D.; Hagihara, K.; Koshimizu, K. and Ohigashi, H. Combinatorial effects of nonsteroidal antiinflammatory drugs and food constituents on production of prostaglandin E2 and tumor necrosis factor-alpha in RAW264.7 murine macrophages. Biosci. Biotechnol. Biochem., 2003, 67, 1056-1062.
92. Pae, M.; Ren, Z.; Meydani, M.; Shang, F.; Smith, D.; Meydani, S.N. and Wu, D. Dietary supplementation with high dose of epigallocatechin-3-gallate promotes inflammatory response in mice. J. Nutr.Biochem.
93. Margolin, K.A. Interleukin-2 in the treatment of renal cancer. Semin. Oncol., 2000, 27, 194-203.
94. Song, M.Y.; Yim, J.Y.; Yim, J.M.; Kang, I.J.; Rho, H.W.; Kim, H.S.; Yhim, H.Y.; Lee, N.R.; Song, E.K.; Kwak, J.Y.; Sohn, M.H. and Yim, C.Y. Use of curcumin to decrease nitric oxide production during the induction of antitumor responses by IL-2. J. Immunother., 2011, 34, 149-164.
95. Aires, V.; Adote, S.; Hichami, A.; Moutairou, K.; Boustani, E.S. and Khan, N.A. Modulation of intracellular calcium concentrations and T cell activation by prickly pear polyphenols. Mol. Cell Biochem., 2004, 260, 103-110.
96. Palucka, K.A.; Taquet, N.; Sanchez-Chapuis, F. and Gluckman, J.C. Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol., 1998, 160, 4587-4595.
97. Crowley, M.; Inaba, K. and Steinman, R.M. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J Exp Med, 1990, 172, 383-386.
98. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 1991, 9, 271-296.
99. Svajger, U.; Obermajer, N. and Jeras, M. Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology, 2010, 129, 525-535.
100. Kim, G.Y.; Cho, H.; Ahn, S.C.; Oh, Y.H.; Lee, C.M. and Park, Y.M. Resveratrol inhibits phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int. Immunopharmacol., 2004, 4, 245-253.
101. Yoneyama, S.; Kawai, K.; Tsuno, N.H.; Okaji, Y.; Asakage, M.; Tsuchiya, T.; Yamada, J.; Sunami, E.; Osada, T.; Kitayama, J.; Takahashi, K. and Nagawa, H. Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J. Allergy. Clin. Immunol., 2008, 121, 209-214.
102. Ahn, S.C.; Kim, G.Y.; Kim, J.H.; Baik, S.W.; Han, M.K.; Lee, H.J.; Moon, D.O.; Lee, C.M.; Kang, J.H.; Kim, B.H.; Oh, Y.H. and Park, Y.M. Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. Biochem. Biophys. Res. Commun., 2004, 313, 148-155.
103. Rogers, N.M.; Kireta, S. and Coates, P.T. Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin. Exp. Immunol., 2010, 162, 460-473.
104. Kim, G.Y.; Kim, K.H.; Lee, S.H.; Yoon, M.S.; Lee, H.J.; Moon, D.O.; Lee, C.M.; Ahn, S.C.; Park, Y.C. and Park, Y.M. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J. Immunol., 2005, 174, 8116-8124.
105. Jeong, Y.I.; Jung, I.D.; Lee, J.S.; Lee, C.M.; Lee, J.D. and Park, Y.M. (-)-Epigallocatechin gallate suppresses indoleamine 2,3dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem. Biophys. Res. Commun., 2007, 354, 1004-1009.
106. Jeong, Y.I.; Kim, S.W.; Jung, I.D.; Lee, J.S.; Chang, J.H.; Lee, C.M.; Chun, S.H.; Yoon, M.S.; Kim, G.T.; Ryu, S.W.; Kim, J.S.; Shin, Y.K.; Lee, W.S.; Shin, H.K.; Lee, J.D. and Park, Y.M. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase CdeltaSTAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J. Biol. Chem., 2009, 284, 3700-3708.
107. Vivier, E.; Raulet, D.H.; Moretta, A.; Caligiuri, M.A.; Zitvogel, L.; Lanier, L.L.; Yokoyama, W.M. and Ugolini, S. Innate or adaptive immunity? The example of natural killer cells. Science, 2011, 331, 44-49.
108. Bachleda, P.; Vrzal, R. and Dvorak, Z. Resveratrol enhances NK cell cytotoxicity: Possible role for aryl hydrocarbon receptor. J. Cell Physiol., 2010, 225, 289-290.
109. Falchetti, R.; Fuggetta, M.P.; Lanzilli, G.; Tricarico, M. and Ravagnan, G. Effects of resveratrol on human immune cell function. Life Sci, 2001, 70, 81-96.
110. Li, T.; Fan, G.X.; Wang, W.; Li, T. and Yuan, Y.K. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. Int. Immunopharmacol., 2007, 7, 1221-1231.
111. Jiang, X.; Patterson, N.M.; Ling, Y.; Xie, J.; Helferich, W.G. and Shapiro, D.J. Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. Endocrinology, 2008, 149, 5366-5373.
112. Bill, M.A.; Bakan, C.; Benson, D.M., Jr.; Fuchs, J.; Young, G. and Lesinski, G.B. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther, 2009, 8, 2726-2735.
113. Yadav, V.S.; Mishra, K.P.; Singh, D.P.; Mehrotra, S. and Singh, V.K. Immunomodulatory effects of curcumin. Immunopharmacol. Immunotoxicol., 2005, 27, 485-497.
114. Guo, T.L.; McCay, J.A.; Zhang, L.X.; Brown, R.D.; You, L.; Karrow, N.A.; Germolec, D.R. and White, K.L., Jr. Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. J. Nutr., 2001, 131, 3251-3258.
115. Lu, C.C. and Chen, J.K. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J. Cell Physiol., 2010, 223, 343-351.
116. Pae, M.; Ren, Z.; Meydani, M.; Shang, F.; Smith, D.; Meydani, S.N. and Wu, D. Dietary supplementation with high dose of epigallocatechin-3-gallate promotes inflammatory response in mice. J. Nutr. Biochem., 2011.
117. See, D.; Mason, S. and Roshan, R. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol. Invest., 2002, 31, 137-153.
118. Kusmartsev, S.; Cheng, F.; Yu, B.; Nefedova, Y.; Sotomayor, E.; Lush, R. and Gabrilovich, D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res., 2003, 63, 4441-4449.
119. Singh, U.P.; Singh, N.P.; Singh, B.; Hofseth, L.J.; Taub, D.D.; Price, R.L.; Nagarkatti, M. and Nagarkatti, P.S. Role of resveratrol induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav. Immun., 2011.
120. de Visser, K.E.; Eichten, A. and Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 2006, 6, 24-37.
121. Dannenberg, A.J. and Subbaramaiah, K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 2003, 4, 431-436.
122. Luo, J.L.; Maeda, S.; Hsu, L.C.; Yagita, H. and Karin, M. Inhibition of NF-kappaB in cancer cells converts inflammationinduced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6, 297-305.
123. Fujiki, H.; Suganuma, M.; Okabe, S.; Sueoka, E.; Suga, K.; Imai, K. and Nakachi, K. A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-) epigallocatechin gallate and green tea--a review. Cancer Detect. Prev., 2000, 24, 91-99.
124. Chan, M.M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem. Pharmacol., 1995, 49, 1551-1556.
125. Lantz, R.C.; Chen, G.J.; Solyom, A.M.; Jolad, S.D. and Timmermann, B.N. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine, 2005, 12, 445-452.
126. Lee, J.J.; Huang, W.T.; Shao, D.Z.; Liao, J.F. and Lin, M.T. Blocking NF-kappaB activation may be an effective strategy in the fever therapy. Jpn. J. Physiol., 2003, 53, 367-375.
127. Calveley, V.L.; Jelveh, S.; Langan, A.; Mahmood, J.; Yeung, I.W.; Van Dyk, J. and Hill, R.P. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat. Res., 173, 602-611.
128. Gao, X.; Xu, Y.X.; Janakiraman, N.; Chapman, R.A. and Gautam, S.C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol., 2001, 62, 1299-1308.
129. Gao, X.; Deeb, D.; Media, J.; Divine, G.; Jiang, H.; Chapman, R.A. and Gautam, S.C. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem. Pharmacol., 2003, 66, 2427-2435.
130. Locksley, R.M.; Killeen, N. and Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104, 487-501.
131. Takeda, K.; Yamaguchi, N.; Akiba, H.; Kojima, Y.; Hayakawa, Y.; Tanner, J.E.; Sayers, T.J.; Seki, N.; Okumura, K.; Yagita, H. and Smyth, M.J. Induction of tumor-specific T cell immunity by anti DR5 antibody therapy. J. Exp. Med., 2004, 199, 437-448.
132. Zerafa, N.; Westwood, J.A.; Cretney, E.; Mitchell, S.; Waring, P.; Iezzi, M. and Smyth, M.J. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol., 2005, 175, 5586-5590.
133. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D.A.; Marsters, S.A.; Blackie, C.; Chang, L.; McMurtrey, A.E.; Hebert, A.; DeForge, L.; Koumenis, I.L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z. and Schwall, R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 1999, 104, 155-162.
134. Onoda, C.; Kuribayashi, K.; Nirasawa, S.; Tsuji, N.; Tanaka, M.; Kobayashi, D. and Watanabe, N. (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int. J. Oncol., 2011, 38, 1403-1408.
135. Shen, Q.; Tian, F.; Jiang, P.; Li, Y.; Zhang, L.; Lu, J. and Li, J. EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 2009, 29, 771-775.
136. Shankar, S.; Chen, Q.; Siddiqui, I.; Sarva, K. and Srivastava, R.K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J. Mol. Signal., 2007, 2, 7.
137. Ganapathy, S.; Chen, Q.; Singh, K.P.; Shankar, S. and Srivastava, R.K. Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor. PLoS One, 2010, 5, e15627.
138. Gill, C.; Walsh, S.E.; Morrissey, C.; Fitzpatrick, J.M. and Watson, R.W. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate, 2007, 67, 1641-1653.
139. Deeb, D.; Jiang, H.; Gao, X.; Al-Holou, S.; Danyluk, A.L.; Dulchavsky, S.A. and Gautam, S.C. Curcumin [1,7-bis(4-hydroxy 3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factorrelated apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J. Pharmacol. Exp. Ther., 2007, 321, 616-625.
140. Andrzejewski, T.; Deeb, D.; Gao, X.; Danyluk, A.; Arbab, A.S.; Dulchavsky, S.A. and Gautam, S.C. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res., 2008, 17, 257-267.
141. Shankar, S.; Ganapathy, S.; Chen, Q. and Srivastava, R.K. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer, 2008, 7, 16.
142. Shankar, S.; Chen, Q.; Sarva, K.; Siddiqui, I. and Srivastava, R.K. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J. Mol. Signal, 2007, 2, 10.
143. Srivastava, R.K.; Chen, Q.; Siddiqui, I.; Sarva, K. and Shankar, S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle, 2007, 6, 2953-2961.
144. Deeb, D.D.; Jiang, H.; Gao, X.; Divine, G.; Dulchavsky, S.A. and Gautam, S.C. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J. Exp. Ther. Oncol., 2005, 5, 81-91.
145. Deeb, D.; Jiang, H.; Gao, X.; Hafner, M.S.; Wong, H.; Divine, G.; Chapman, R.A.; Dulchavsky, S.A. and Gautam, S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther., 2004, 3, 803-812.
146. Deeb, D.; Xu, Y.X.; Jiang, H.; Gao, X.; Janakiraman, N.; Chapman, R.A. and Gautam, S.C. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther., 2003, 2, 95-103.
147. Szliszka, E. and Krol, W. Soy isoflavones augment the effect of TRAIL-mediated apoptotic death in prostate cancer cells. Oncol. Rep., 2011, 26, 533-541.
148. Nozawa, F.; Itami, A.; Saruc, M.; Kim, M.; Standop, J.; Picha, K.S.; Cowan, K.H. and Pour, P.M. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas, 2004, 29, 45-52.
149. Basu, A. and Haldar, S. Combinatorial effect of epigallocatechin-3gallate and TRAIL on pancreatic cancer cell death. Int. J. Oncol., 2009, 34, 281-286.
150. Khanbolooki, S.; Nawrocki, S.T.; Arumugam, T.; Andtbacka, R.; Pino, M.S.; Kurzrock, R.; Logsdon, C.D.; Abbruzzese, J.L. and McConkey, D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther., 2006, 5, 2251-2260.
151. Gao, X.; Deeb, D.; Jiang, H.; Liu, Y.B.; Dulchavsky, S.A. and Gautam, S.C. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J. Exp. Ther. Oncol., 2005, 5, 39-48.
152. Siegelin, M.D.; Habel, A. and Gaiser, T. Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci. Lett., 2008, 448, 161-165.
153. Siegelin, M.D.; Siegelin, Y.; Habel, A. and Gaiser, T. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett., 2009, 453, 92-97.
154. Siddiqui, I.A.; Malik, A.; Adhami, V.M.; Asim, M.; Hafeez, B.B.; Sarfaraz, S. and Mukhtar, H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene, 2008, 27, 2055-2063.
155. Nishikawa, T.; Nakajima, T.; Moriguchi, M.; Jo, M.; Sekoguchi, S.; Ishii, M.; Takashima, H.; Katagishi, T.; Kimura, H.; Minami, M.; Itoh, Y.; Kagawa, K. and Okanoue, T. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol, 2006, 44, 1074-1082.
156. Jin, C.Y.; Park, C.; Kim, G.Y.; Lee, S.J.; Kim, W.J. and Choi, Y.H. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem. Biol. Interact., 2009, 180, 143-150.
157. Jin, C.Y.; Park, C.; Moon, S.K.; Kim, G.Y.; Kwon, T.K.; Lee, S.J.; Kim, W.J. and Choi, Y.H. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs, 2009, 20, 713-722.
158. Jin, C.Y.; Park, C.; Cheong, J.; Choi, B.T.; Lee, T.H.; Lee, J.D.; Lee, W.H.; Kim, G.Y.; Ryu, C.H. and Choi, Y.H. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett, 2007, 257, 56-64.
159. Gatsinzi, T. and Iverfeldt, K. Sensitization to TRAIL-induced apoptosis in human neuroblastoma SK-N-AS cells by NF-kappaB inhibitors is dependent on reactive oxygen species (ROS). J. Neurooncol., 2011, 104, 459-472.
160. Fulda, S. and Debatin, K.M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur. J. Cancer, 2005, 41, 786-798.
161. Fulda, S. and Debatin, K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64, 337 346.
162. Hussain, A.R.; Ahmed, M.; Al-Jomah, N.A.; Khan, A.S.; Manogaran, P.; Sultana, M.; Abubaker, J.; Platanias, L.C.; Al-Kuraya, K.S. and Uddin, S. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol. Cancer Ther., 2008, 7, 3318-3329.
163. Wahl, H.; Tan, L.; Griffith, K.; Choi, M. and Liu, J.R. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol. Oncol., 2007, 105, 104-112.
164. Jung, E.M.; Lim, J.H.; Lee, T.J.; Park, J.W.; Choi, K.S. and Kwon, T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis, 2005, 26, 1905-1913.
165. Pavet, V.; Beyrath, J.; Pardin, C.; Morizot, A.; Lechner, M.C.; Briand, J.P.; Wendland, M.; Maison, W.; Fournel, S.; Micheau, O.; Guichard, G. and Gronemeyer, H. Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity. Cancer Res., 2010, 70, 1101-1110.
166. Delmas, D.; Rebe, C.; Micheau, O.; Athias, A.; Gambert, P.; Grazide, S.; Laurent, G.; Latruffe, N. and Solary, E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23, 8979-8986.
167. Pohland, T.; Wagner, S.; Mahyar-Roemer, M. and Roemer, K. Bax and Bak are the critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive resveratrol. Anticancer Drugs, 2006, 17, 471-478.
168. Hueber, A.O.; Bernard, A.M.; Herincs, Z.; Couzinet, A. and He, H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep., 2002, 3, 190-196.
169. Grassme, H.; Jekle, A.; Riehle, A.; Schwarz, H.; Berger, J.; Sandhoff, K.; Kolesnick, R. and Gulbins, E. CD95 signaling via ceramide-rich membrane rafts. J. Biolog.Chem., 2001, 276, 20589-20596.
170. Opipari, A.W., Jr.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A. and Liu, J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res., 2004, 64, 696-703.
171. Colin, D.; Limagne, E.; Jeanningros, S.; Jacquel, A.; Lizard, G.; Athias, A.; Gambert, P.; Hichami, A.; Latruffe, N.; Solary, E. and Delmas, D. Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res (Phila), 2011, 4, 1095-1106.
172. Delmas, D. and Lin, H.Y. Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: Consequences in bioavailability and activities. Mol. Nutr. Food Res., 2011.
173. Delmas, D.; Rebe, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkaoui-Malki, M.; Jannin, B.; Dubrez-Daloz, L.; Latruffe, N. and Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem., 2003, 278, 41482-41490.
174. Shiraki, K.; Tsuji, N.; Shioda, T.; Isselbacher, K.J. and Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA, 1997, 94, 6420-6425.
175. Zeytun, A.; Hassuneh, M.; Nagarkatti, M. and Nagarkatti, P.S. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood, 1997, 90, 1952-1959.
176. Seino, K.; Kayagaki, N.; Fukao, K.; Okumura, K. and Yagita, H. Rejection of Fas ligand-expressing grafts. Transplant. Proc., 1997, 29, 1092-1093.
177. Hoffmann, J.; Junker, H.; Schmieder, A.; Venz, S.; Brandt, R.; Multhoff, G.; Falk, W. and Radons, J. EGCG downregulates IL1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem. Pharmacol., 2011.
178. Jurrmann, N.; Brigelius-Flohe, R. and Bol, G.F. Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J. Nutr., 2005, 135, 1859-1864.
179. Sriram, N.; Kalayarasan, S. and Sudhandiran, G. Epigallocatechin3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm. Pharmacol. Ther., 2009, 22, 221-236.
180. Mitsuyama, K.; Matsumoto, S.; Masuda, J.; Yamasakii, H.; Kuwaki, K.; Takedatsu, H. and Sata, M. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res., 2007, 27, 3749-3756.
181. Ji, G.; Yang, Q.; Hao, J.; Guo, L.; Chen, X.; Hu, J.; Leng, L. and Jiang, Z. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int. Immunopharmacol., 2011, 11, 762-768.
182. Xia, J.; Song, X.; Bi, Z.; Chu, W. and Wan, Y. UV-induced NFkappaB activation and expression of IL-6 is attenuated by (-) epigallocatechin-3-gallate in cultured human keratinocytes in vitro. Int. J. Mol. Med., 2005, 16, 943-950
183. Cohen, A.N.; Veena, M.S.; Srivatsan, E.S. and Wang, M.B. Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch. Otolaryngol. Head Neck Surg., 2009, 135, 190-197.
184. Wang, Y.; Yu, C.; Pan, Y.; Yang, X.; Huang, Y.; Feng, Z.; Li, X.; Yang, S. and Liang, G. A Novel Synthetic Mono-Carbonyl Analogue of Curcumin, A13, Exhibits Anti-Inflammatory Effects In vivo by Inhibition of Inflammatory Mediators. Inflammation, 2011.
185. Paradkar, P.N.; Blum, P.S.; Berhow, M.A.; Baumann, H. and Kuo, S.M. Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett., 2004, 215, 21-28.
186. Bharti, A.C.; Donato, N. and Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol., 2003, 171, 3863-3871.
187. Chakravarti, N.; Myers, J.N. and Aggarwal, B.B. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int. J. Cancer, 2006, 119, 1268-1275.
188. Wung, B.S.; Hsu, M.C.; Wu, C.C. and Hsieh, C.W. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci., 2005, 78, 389-397.
189. Masuda, M.; Suzui, M. and Weinstein, I.B. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res., 2001, 7, 4220-4229.
190. Natarajan, C. and Bright, J.J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol., 2002, 168, 6506-6513.
191. Reddy, S. and Aggarwal, B.B. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett., 1994, 341, 19-22.
192. Hong, R.L.; Spohn, W.H. and Hung, M.C. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res., 1999, 5, 1884-1891.
193. Korutla, L. and Kumar, R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta, 1994, 1224, 597-600.
194. Saydmohammed, M.; Joseph, D. and Syed, V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell Biochem., 2010, 110, 447-456.
195. Seo, J.H.; Jeong, K.J.; Oh, W.J.; Sul, H.J.; Sohn, J.S.; Kim, Y.K.; Chodo, Y.; Kang, J.K.; Park, C.G. and Lee, H.Y. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett., 288, 50-56.
196. Kim, H.Y.; Park, E.J.; Joe, E.H. and Jou, I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol., 2003, 171, 6072-6079.
197. Zhu, B.H.; Chen, H.Y.; Zhan, W.H.; Wang, C.Y.; Cai, S.R.; Wang, Z.; Zhang, C.H. and He, Y.L. (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J Gastroenterol, 2011, 17, 2315-2325.
198. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest., 2002, 109, 1139-1142.
199. Damianaki, A.; Bakogeorgou, E.; Kampa, M.; Notas, G.; Hatzoglou, A.; Panagiotou, S.; Gemetzi, C.; Kouroumalis, E.; Martin, P.M. and Castanas, E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell Biochem., 2000, 78, 429-441.
200. Sgambato, A.; Ardito, R.; Faraglia, B.; Boninsegna, A.; Wolf, F.I. and Cittadini, A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat. Res., 2001, 496, 171-180.
201. Afaq, F.; Adhami, V.M.; Ahmad, N. and Mukhtar, H. Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci., 2002, 7, d784-792.
202. Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K. and Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun., 2003, 309, 1017-1026.
203. Awad, A.B.; Burr, A.T. and Fink, C.S. Effect of resveratrol and beta-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 72, 219-226.
204. Cadenas, S. and Barja, G. Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Radic. Biol. Med., 1999, 26, 1531-1537.
205. Afaq, F.; Adhami, V.M. and Ahmad, N. Prevention of shortterm ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol., 2003, 186, 28-37.
206. Wu, H.J. and Chan, W.H. Genistein protects methylglyoxalinduced oxidative DNA damage and cell injury in human mononuclear cells. Toxicol In Vitro, 2007, 21, 335-342.
207. Chang, W.H.; Liu, J.J.; Chen, C.H.; Huang, T.S. and Lu, F.J. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by fermented soy milk. Nutr. Cancer, 2002, 43, 214-226.
208. Hadi, S.M.; Asad, S.F.; Singh, S. and Ahmad, A. Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life, 2000, 50, 167-171.
209. de la Lastra, C.A. and Villegas, I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans., 2007, 35, 1156-1160.
210. Prochazkova, D.; Bousova, I. and Wilhelmova, N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia, 2011, 82, 513-523.
211. Lambert, J.D. and Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys., 2010, 501, 65-72.
212. Kovacic, P. and Somanathan, R. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety. Oxid. Med. Cell Longev., 2010, 3, 86-100.
213. Nichols, J.A. and Katiyar, S.K. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res, 2010, 302, 71-83.
214. Ahmad, A.; Syed, F.A.; Singh, S. and Hadi, S.M. Prooxidant activity of resveratrol in the presence of copper ions: Mutagenicity in plasmid DNA. Toxicol. Lett., 2005.
215. Bhat, S.H.; Azmi, A.S. and Hadi, S.M. Prooxidant DNA breakage induced by caffeic acid in human peripheral lymphocytes: Involvement of endogenous copper and a putative mechanism for anticancer properties. Toxicol. Appl. Pharmacol., 2006.
216. Goodwin, J.S. and Ceuppens, J. Regulation of the immune response by prostaglandins. J Clin Immunol, 1983, 3, 295-315.
217. Banerjee, S.; Manna, S.; Mukherjee, S.; Pal, D.; Panda, C.K. and Das, S. Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression. Asian Pac. J. Cancer Prev., 2006, 7, 661-666.
218. Swami, S.; Krishnan, A.V.; Moreno, J.; Bhattacharyya, R.S.; Gardner, C.; Brooks, J.D.; Peehl, D.M. and Feldman, D. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int. J. Cancer, 2009, 124, 2050-2059.
219. Huang, M.T.; Lysz, T.; Ferraro, T.; Abidi, T.F.; Laskin, J.D. and Conney, A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res., 1991, 51, 813-819.
220. Tunstall, R.G.; Sharma, R.A.; Perkins, S.; Sale, S.; Singh, R.; Farmer, P.B.; Steward, W.P. and Gescher, A.J. Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials. Eur. J. Cancer, 2006, 42, 415-421.
221. Chun, K.S.; Keum, Y.S.; Han, S.S.; Song, Y.S.; Kim, S.H. and Surh, Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis, 2003, 24, 1515-1524.
222. MacCarrone, M.; Lorenzon, T.; Guerrieri, P. and Agro, A.F. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem., 1999, 265, 27-34.
223. Knight, J.; Taylor, G.W.; Wright, P.; Clare, A.S. and Rowley, A.F. Eicosanoid biosynthesis in an advanced deuterostomate invertebrate, the sea squirt (Ciona intestinalis). Biochim. Biophys. Acta, 1999, 1436, 467-478.
224. Eling, T.E.; Thompson, D.C.; Foureman, G.L.; Curtis, J.F. and Hughes, M.F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol., 1990, 30, 1-45.
225. Kulmacz, R.J. and Wang, L.H. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J. Biol. Chem., 1995, 270, 24019-24023.
226. Maccarrone, M.; Putti, S. and Finazzi Agro, A. Nitric oxide donors activate the cyclo-oxygenase and peroxidase activities of prostaglandin H synthase. FEBS Lett., 1997, 410, 470-476.
227. Pace-Asciak, C.R.; Hahn, S.; Diamandis, E.P.; Soleas, G. and Goldberg, D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta, 1995, 235, 207-219.
228. Martinez, J. and Moreno, J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol, 2000, 59, 865-870.
229. Moreno, J.J. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J. Pharmacol. Exp. Ther., 2000, 294, 333-338.
230. Kimura, Y.; Okuda, H. and Arichi, S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta, 1985, 834, 275-278.
231. Rotondo, S.; Rajtar, G.; Manarini, S.; Celardo, A.; Rotillo, D.; de Gaetano, G.; Evangelista, V. and Cerletti, C. Effect of transresveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br. J. Pharmacol., 1998, 123, 1691-1699.
232. Kimura, Y.; Okuda, H. and Kubo, M. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J. Ethnopharmacol., 1995, 45, 131-139.
233. Johnson, J.L. and Maddipati, K.R. Paradoxical effects of resveratrol on the two prostaglandin H synthases. Prostaglandins Other Lipid Mediat., 1998, 56, 131-143.
234. Jang, M. and Pezzuto, J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin Res., 1999, 25, 65-77.
235. Waffo-Teguo, P.; Hawthorne, M.E.; Cuendet, M.; Merillon, J.M.; Kinghorn, A.D.; Pezzuto, J.M. and Mehta, R.G. Potential cancerchemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr. Cancer, 2001, 40, 173-179.
236. Rimando, A.M.; Cuendet, M.; Desmarchelier, C.; Mehta, R.G.; Pezzuto, J.M. and Duke, S.O. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J. Agric. Food Chem., 2002, 50, 3453-3457.
237. Gerhauser, C.; Klimo, K.; Heiss, E.; Neumann, I.; Gamal-Eldeen, A.; Knauft, J.; Liu, G.Y.; Sitthimonchai, S. and Frank, N. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat. Res., 2003, 523-524, 163-172.
238. Shin, N.H.; Ryu, S.Y.; Lee, H.; Min, K.R. and Kim, Y. Inhibitory effects of hydroxystilbenes on cyclooxygenase from sheep seminal vesicles. Planta Med, 1998, 64, 283-284.
239. Szewczuk, L.M.; Forti, L.; Stivala, L.A. and Penning, T.M. Resveratrol is a peroxidase mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem., 2004.
240. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T. and Jager, W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem., 2004, 12, 5571-5578.
241. Subbaramaiah, K.; Chung, W.J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J.M. and Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 1998, 273, 21875-21882.
242. Subbaramaiah, K.; Michaluart, P.; Chung, W.J.; Tanabe, T.; Telang, N. and Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. NY Acad. Sci., 1999, 889, 214-223.
243. Subbaramaiah, K. and Dannenberg, A.J. Resveratrol inhibits the expression of cyclooxygenase-2 in mammary epithelial cells. Adv. Exp. Med. Biol., 2001, 492, 147-157.
244. Mutoh, M.; Takahashi, M.; Fukuda, K.; Matsushima-Hibiya, Y.; Mutoh, H.; Sugimura, T. and Wakabayashi, K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis, 2000, 21, 959-963.
245. Wyke, S.M.; Russell, S.T. and Tisdale, M.J. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer, 2004.
246. Shen, F.; Chen, S.J.; Dong, X.J.; Zhong, H.; Li, Y.T. and Cheng, G.F. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J. Asian Nat. Prod. Res., 2003, 5, 151-157.
247. Wolter, F.; Turchanowa, L. and Stein, J. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis, 2003, 24, 469-474.
248. O'Leary, K.A.; de Pascual-Tereasa, S.; Needs, P.W.; Bao, Y.P.; O'Brien, N.M. and Williamson, G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat. Res., 2004, 551, 245-254.
249. Li, Z.G.; Hong, T.; Shimada, Y.; Komoto, I.; Kawabe, A.; Ding, Y.; Kaganoi, J.; Hashimoto, Y. and Imamura, M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 2002, 23, 1531-1536.
250. Aziz, M.; Afaq, F. and Ahmad, N. Prevention of ultraviolet B radiation -damage by resveratrol in mouse skin is mediated via modulation in Survivin. Photochem. Photobiol., 2004.
251. Ziegler, C.C.; Rainwater, L.; Whelan, J. and McEntee, M.F. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J. Nutr., 2004, 134, 5-10.
252. Sale, S.; Tunstall, R.G.; Ruparelia, K.C.; Potter, G.A.; Steward, W.P. and Gescher, A.J. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer, 2005.
253. Jiang, H.; Deng, C.S.; Zhang, M. and Xia, J. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J. Gastroenterol., 2006, 12, 3848-3853.
254. Shishodia, S.; Potdar, P.; Gairola, C.G. and Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis, 2003, 24, 1269-1279.
255. Sharma, C.; Kaur, J.; Shishodia, S.; Aggarwal, B.B. and Ralhan, R. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology, 2006, 228, 1-15.
256. Pinto, M.C.; Garcia-Barrado, J.A. and Macias, P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J. Agric. Food Chem., 1999, 47, 4842-4846.
257. Pinto Mdel, C.; Garcia-Barrado, J.A. and Macias, P. Oxidation of resveratrol catalyzed by soybean lipoxygenase. J. Agric. Food Chem, 2003, 51, 1653-1657.
258. Pace-Asciak, C.R. Hepoxilins. Gen Pharmacol, 1993, 24, 805-810.
259. Grivennikov, S.I.; Greten, F.R. and Karin, M. Immunity, inflammation, and cancer. Cell, 140, 883-899.
260. Sun, C.; Hu, Y.; Liu, X.; Wu, T.; Wang, Y.; He, W. and Wei, W. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet. Cytogenet., 2006, 165, 9-19.
261. Holmes-McNary, M. and Baldwin, A.S., Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res., 2000, 60, 3477-3483.
262. Adhami, V.M.; Afaq, F. and Ahmad, N. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia, 2003, 5, 74-82.
263. Manna, S.K.; Mukhopadhyay, A. and Aggarwal, B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164, 6509-6519.
264. Karin, M. and Greten, F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 2005, 5, 749-759.
265. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature, 2006, 441, 431-436.
266. Pendurthi, U.R.; Meng, F.; Mackman, N. and Rao, L.V. Mechanism of resveratrol-mediated suppression of tissue factor gene expression. Thromb. Haemost., 2002, 87, 155-162.
267. Slater, S.J.; Seiz, J.L.; Cook, A.C.; Stagliano, B.A. and Buzas, C.J. Inhibition of protein kinase C by resveratrol. Biochim. Biophys. Acta, 2003, 1637, 59-69.
268. Storz, P.; Doeppler, H. and Toker, A. Activation Loop Phosphorylation Controls Protein Kinase D-Dependent Activation of Nuclear Factor {kappa}-B. Mol. Pharmacol., 2004.
269. Narayanan, B.A.; Narayanan, N.K.; Stoner, G.D. and Bullock, B.P. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci., 2002, 70, 1821-1839.
270. Jo, E.H.; Hong, H.D.; Ahn, N.C.; Jung, J.W.; Yang, S.R.; Park, J.S.; Kim, S.H.; Lee, Y.S. and Kang, K.S. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J. Agric. Food Chem., 2004, 52, 1715-1719.
271. Jazirehi, A.R. and Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxelinduced apoptosis. Mol. Cancer Ther., 2004, 3, 71-84.
272. Kim, Y.A.; Choi, B.T.; Lee, Y.T.; Park, D.I.; Rhee, S.H.; Park, K.Y. and Choi, Y.H. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol. Rep., 2004, 11, 441-446.
273. Hsieh, T.C.; Burfeind, P.; Laud, K.; Backer, J.M.; Traganos, F.; Darzynkiewicz, Z. and Wu, J.M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol., 1999, 15, 245-252.
274. Taylor, B.S.; de Vera, M.E.; Ganster, R.W.; Wang, Q.; Shapiro, R.A.; Morris, S.M., Jr.; Billiar, T.R. and Geller, D.A. Multiple NFkappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biolog.Chem., 1998, 273, 15148-15156.
275. Sheppard, K.A.; Phelps, K.M.; Williams, A.J.; Thanos, D.; Glass, C.K.; Rosenfeld, M.G.; Gerritsen, M.E. and Collins, T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biological Chem., 1998, 273, 29291-29294.
276. Sheppard, K.A.; Rose, D.W.; Haque, Z.K.; Kurokawa, R.; McInerney, E.; Westin, S.; Thanos, D.; Rosenfeld, M.G.; Glass, C.K. and Collins, T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol, 1999, 19, 6367-6378.
277. Zhong, H.; May, M.J.; Jimi, E. and Ghosh, S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell, 2002, 9, 625-636.
278. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B. and Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-196.
279. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A. and Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J, 2004.
280. Donnelly, L.E.; Newton, R.; Kennedy, G.E.; Fenwick, P.S.; Leung, R.H.; Ito, K.; Russell, R.E. and Barnes, P.J. Anti-inflammatory Effects of Resveratrol in Lung Epithelial Cells: Molecular Mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287, L774-783.
281. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431, 350-355.
282. Calin, G.A. and Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 2006, 6, 857-866.
283. Tili, E.; Michaille, J.J.; Costinean, S. and Croce, C.M. MicroRNAs, the immune system and rheumatic disease. Nat. Clin. Pract. Rheumatol., 2008, 4, 534-541.
284. Taganov, K.D.; Boldin, M.P.; Chang, K.J. and Baltimore, D. NFkappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA, 2006, 103, 12481-12486.
285. Perry, M.M.; Moschos, S.A.; Williams, A.E.; Shepherd, N.J.; Larner-Svensson, H.M. and Lindsay, M.A. Rapid changes in microRNA-146a expression negatively regulate the IL-1betainduced inflammatory response in human lung alveolar epithelial cells. J. Immunol., 2008, 180, 5689-5698.
286. Tili, E.; Croce, C.M. and Michaille, J.J. miR-155: on the crosstalk between inflammation and cancer. Int. Rev. Immunol., 2009, 28, 264-284.
287. Slaby, O.; Svoboda, M.; Fabian, P.; Smerdova, T.; Knoflickova, D.; Bednarikova, M.; Nenutil, R. and Vyzula, R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology, 2007, 72, 397-402.
288. Tili, E.; Michaille, J.J.; Alder, H.; Volinia, S.; Delmas, D.; Latruffe, N. and Croce, C.M. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem. Pharmacol., 2010.
289. Tili, E.; Michaille, J.J.; Adair, B.; Alder, H.; Limagne, E.; Taccioli, C.; Ferracin, M.; Delmas, D.; Latruffe, N. and Croce, C.M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis, 2010.
290. Negulescu, P.A.; Shastri, N. and Cahalan, M.D. Intracellular calcium dependence of gene expression in single T lymphocytes. Proc. Natl. Acad. Sci. USA, 1994, 91, 2873-2877.
291. Qu, B.; Al-Ansary, D.; Kummerow, C.; Hoth, M. and Schwarz, E.C. ORAI-mediated calcium influx in T cell proliferation, apoptosis and tolerance. Cell Calcium, 2011, 50, 261-269.
292. Shin, D.H.; Seo, E.Y.; Pang, B.; Nam, J.H.; Kim, H.S.; Kim, W.K. and Kim, S.J. Inhibition of Ca2+-release-activated Ca2+ channel (CRAC) and K+ channels by curcumin in Jurkat-T cells. J Pharmacol. Sci11 5, 144-154.
293. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr. and Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32, 1377-1382.
294. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P. and Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 1246-1252.
295. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L. and Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res, 2009, 53, S7-15.
296. Nunes, T.; Almeida, L.; Rocha, J.F.; Falcao, A.; Fernandes-Lopes, C.; Loureiro, A.I.; Wright, L.; Vaz-da-Silva, M. and Soares-da-Silva, P. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol., 2009, 49, 1477-1482.
297. Gescher, A.J. and Steward, W.P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 953-957.
298. Patel, K.R.; Brown, V.A.; Jones, D.J.; Britton, R.G.; Hemingway, D.; Miller, A.S.; West, K.P.; Booth, T.D.; Perloff, M.; Crowell, J.A.; Brenner, D.E.; Steward, W.P.; Gescher, A.J. and Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res., 2010, 70, 7392-7399.
299. Baur, J.A. and Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
300. Clement, M.V.; Hirpara, J.L.; Chawdhury, S.H. and Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 1998, 92, 996-1002.
301. Lu, J.; Ho, C.H.; Ghai, G. and Chen, K.Y. Resveratrol analog, 3,4,5,4'-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis, 2001, 22, 321-328.
302. Colin, D.; Gimazane, A.; Lizard, G.; Izard, J.C.; Solary, E.; Latruffe, N. and Delmas, D. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int. J. Cancer, 2009, 124, 2780-2788.
303. Asensi, M.; Medina, I.; Ortega, A.; Carretero, J.; Bano, M.C.; Obrador, E. and Estrela, J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med, 2002, 33, 387-398.
304. Patel, K.R.; Scott, E.; Brown, V.A.; Gescher, A.J.; Steward, W.P. and Brown, K. Clinical trials of resveratrol. Ann. NY Acad Sci., 2011, 1215, 161-169.
305. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Perloff, M.; Booth, T.D.; Vasilinin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; Brown, K.; Steward, W.P.; Gescher, A.J. and Brenner, D.E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res., 2010, 70, 9003-9011.
306. Bronikowska, J.; Szliszka, E.; Czuba, Z.P.; Zwolinski, D.; Szmydki, D. and Krol, W. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules, 2010, 15, 2000-2015.
307. Szliszka, E.; Czuba, Z.P.; Jernas, K. and Krol, W. Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci, 2008, 9, 56-64.
308. Ivanov, V.N.; Partridge, M.A.; Johnson, G.E.; Huang, S.X.; Zhou, H. and Hei, T.K. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell Res., 2008, 314, 1163-1176.